Objective To review the current evidence regarding pregnancy-related issues in multiple
sclerosis (MS) and to provide recommendations specific for each of them. Research design …

Purpose of this Review: This article is a systematic review on the influence pregnancy has
on multiple sclerosis and the resulting impact of disease-modifying therapies. Findings …

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS). The
activation of inflammatory cells is crucial for the development of MS and is shown to induce …

Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, and degenerative
disease that is up to three times more frequent in young women. MS does not alter fertility …

Ocrelizumab is a recombinant humanized monoclonal antibody selectively targeting CD20-
expressing B cells. The effect of ocrelizumab on primary progressive multiple sclerosis …

The earlier the diagnosis of multiple sclerosis (MS), the sooner disease-modifying
treatments can be initiated. However, significant delays still occur in developing countries …

Multiple sclerosis (MS) management presently aims to reach a state of no (or minimal)
evidence of disease activity. The development and commercialization of new drugs has led …

Background Optimizing multiple sclerosis treatment warrants understanding of changes in
physical, mental, and social health. Objective To assess the impact of natalizumab on …

Background Recent studies emphasise the importance of timely diagnosis and early
initiation of disease-modifying treatment in the long-term prognosis of multiple sclerosis …

Background: Despite the abundance of information concerning ocrelizumab in phase III
clinical trials, there is scarce evidence regarding real-world patient profiles. Objective: The …